Compare THRM & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRM | REPL |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.7M | 692.8M |
| IPO Year | 1996 | 2018 |
| Metric | THRM | REPL |
|---|---|---|
| Price | $29.31 | $6.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $39.40 | $11.13 |
| AVG Volume (30 Days) | 194.0K | ★ 2.3M |
| Earning Date | 04-23-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $554,979,000.00 | N/A |
| Revenue This Year | $4.90 | N/A |
| Revenue Next Year | $7.19 | N/A |
| P/E Ratio | $49.77 | ★ N/A |
| Revenue Growth | ★ 50.16 | N/A |
| 52 Week Low | $22.90 | $2.68 |
| 52 Week High | $39.48 | $13.24 |
| Indicator | THRM | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 29.54 |
| Support Level | $27.02 | $4.39 |
| Resistance Level | $29.37 | $4.95 |
| Average True Range (ATR) | 0.88 | 0.83 |
| MACD | 0.33 | -0.23 |
| Stochastic Oscillator | 84.96 | 0.00 |
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the USA, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.